Matches in Nanopublications for { ?s ?p "Recent studies from our laboratory [63] have shown that treatment of mammary epithelial cells with Wnt-1 or Wnt-5a activates ErbB1 and the MAPK cascade. The effect is rapid and can be blocked by an ErbB1 mAb that interferes with ligand binding, or by metalloproteinase inhibitors. These results suggest that in a manner similar to that described for GPCR agonists, Wnt binding to Fz transactivates ErbB1 by increasing the availability of an ErbB1 ligand. Interestingly, Wnt-transactivated ErbB1 was responsible for MAPK activation and for the increased levels of cyclin D1 that were found in Wnt-1-expressing cells." ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- _6 value "Recent studies from our laboratory [63] have shown that treatment of mammary epithelial cells with Wnt-1 or Wnt-5a activates ErbB1 and the MAPK cascade. The effect is rapid and can be blocked by an ErbB1 mAb that interferes with ligand binding, or by metalloproteinase inhibitors. These results suggest that in a manner similar to that described for GPCR agonists, Wnt binding to Fz transactivates ErbB1 by increasing the availability of an ErbB1 ligand. Interestingly, Wnt-transactivated ErbB1 was responsible for MAPK activation and for the increased levels of cyclin D1 that were found in Wnt-1-expressing cells." provenance.
- _5 value "Recent studies from our laboratory [63] have shown that treatment of mammary epithelial cells with Wnt-1 or Wnt-5a activates ErbB1 and the MAPK cascade. The effect is rapid and can be blocked by an ErbB1 mAb that interferes with ligand binding, or by metalloproteinase inhibitors. These results suggest that in a manner similar to that described for GPCR agonists, Wnt binding to Fz transactivates ErbB1 by increasing the availability of an ErbB1 ligand. Interestingly, Wnt-transactivated ErbB1 was responsible for MAPK activation and for the increased levels of cyclin D1 that were found in Wnt-1-expressing cells." provenance.
- _10 value "Recent studies from our laboratory [63] have shown that treatment of mammary epithelial cells with Wnt-1 or Wnt-5a activates ErbB1 and the MAPK cascade. The effect is rapid and can be blocked by an ErbB1 mAb that interferes with ligand binding, or by metalloproteinase inhibitors. These results suggest that in a manner similar to that described for GPCR agonists, Wnt binding to Fz transactivates ErbB1 by increasing the availability of an ErbB1 ligand. Interestingly, Wnt-transactivated ErbB1 was responsible for MAPK activation and for the increased levels of cyclin D1 that were found in Wnt-1-expressing cells." provenance.
- _10 value "Recent studies from our laboratory [63] have shown that treatment of mammary epithelial cells with Wnt-1 or Wnt-5a activates ErbB1 and the MAPK cascade. The effect is rapid and can be blocked by an ErbB1 mAb that interferes with ligand binding, or by metalloproteinase inhibitors. These results suggest that in a manner similar to that described for GPCR agonists, Wnt binding to Fz transactivates ErbB1 by increasing the availability of an ErbB1 ligand. Interestingly, Wnt-transactivated ErbB1 was responsible for MAPK activation and for the increased levels of cyclin D1 that were found in Wnt-1-expressing cells." provenance.